Back
Common Mechanism - IBBIS
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: International Biosecurity and Biosafety Initiative
Relevant to AI safety discussions around dual-use technology governance and biosecurity, particularly as AI tools accelerate capabilities in synthetic biology and create new risks requiring coordinated screening mechanisms.
Metadata
Importance: 52/100webpagehomepage
Summary
IBBIS (International Biosecurity and Biosafety Initiative for Science) describes their Common Mechanism, a shared screening system designed to help DNA synthesis providers screen orders for dangerous sequences. The initiative aims to establish a global standard for biosecurity screening to prevent misuse of synthetic biology tools for creating biological weapons or dangerous pathogens.
Key Points
- •The Common Mechanism provides a shared technical infrastructure for screening DNA synthesis orders against databases of dangerous sequences
- •Designed to help smaller DNA synthesis companies access biosecurity screening that they could not develop independently
- •Supports global harmonization of biosecurity standards across the synthetic biology industry
- •Addresses a key dual-use research concern: that DNA synthesis could enable creation of dangerous pathogens or bioweapons
- •Represents a coordinated governance approach to managing biosecurity risks in an emerging technology sector
Cited by 2 pages
| Page | Type | Quality |
|---|---|---|
| IBBIS (International Biosecurity and Biosafety Initiative for Science) | Organization | 60.0 |
| Is EA Biosecurity Work Limited to Restricting LLM Biological Use? | Analysis | 55.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 202611 KB
- [About](https://ibbis.bio/about/)
- [People](https://ibbis.bio/about/people/)
- [Careers](https://ibbis.bio/about/careers/)
- [News](https://ibbis.bio/news/)
- [Our Work](https://ibbis.bio/our-work/)
- [Commec Sequence Screening](https://ibbis.bio/our-work/common-mechanism/)
- [Customer Screening](https://ibbis.bio/our-work/customer-screening/)
- [Global Synthesis Map](https://ibbis.bio/our-work/global-dna-synthesis-map/)
- [International Standards](https://ibbis.bio/our-work/international-screening-standards/)
- [Sequence Biosecurity Standards](https://ibbis.bio/our-work/sequence-biosecurity-standards/)
- [Vulnerability Disclosure](https://ibbis.bio/our-work/vulnerability-disclosure/)
- [Contact](https://ibbis.bio/contact/)
[](https://ibbis.bio/)
- [About](https://ibbis.bio/about/)
- [People](https://ibbis.bio/about/people/)
- [Careers](https://ibbis.bio/about/careers/)
- [News](https://ibbis.bio/news/)
- [Our Work](https://ibbis.bio/our-work/)
- [Commec Sequence Screening](https://ibbis.bio/our-work/common-mechanism/)
- [Customer Screening](https://ibbis.bio/our-work/customer-screening/)
- [Global Synthesis Map](https://ibbis.bio/our-work/global-dna-synthesis-map/)
- [International Standards](https://ibbis.bio/our-work/international-screening-standards/)
- [Sequence Biosecurity Standards](https://ibbis.bio/our-work/sequence-biosecurity-standards/)
- [Vulnerability Disclosure](https://ibbis.bio/our-work/vulnerability-disclosure/)
- [Contact](https://ibbis.bio/contact/)
Common Mechanism
# **A free, open-source, globally-available tool for synthesis screening**
The Common Mechanism helps providers of synthetic DNA and RNA screen orders efficiently, securely, and in compliance with global biosecurity standards. In order to balance access and security, providers must both:
1. **Recognize potentially risky sequences**, by screening for sequences of concern like toxins and pathogen genes
2. **Decide whether to trust customers** with ordered sequences, by screening for legitimacy
To support this process, IBBIS provides free, distributed, open-source, automated [software for screening sequences](https://ibbis.bio/our-work/common-mechanism/get-started/) of nucleic acids (including DNA and RNA) as well as [customer screening](https://ibbis.bio/our-work/customer-screening/) resources.
Launch
v0.1 released in May 2024
Now
Ongoing development in response to user needs and emerging standards
Future
A robust, globally-available baseline for synthesis screening
## Challenge: preserving access while preventing misuse
Accessible and affordable synthetic nucleic acids are essential for modern biotechnology. However, for nearly 20 years, industry leaders have recognized that some sequences, such as those that can reconstruct pathogen genomes or engineer dangerous agents, should only be sent to trusted customers.
Synthetic nucleic acids hav
... (truncated, 11 KB total)Resource ID:
f9d51c2641d1ac53 | Stable ID: NzI0ODM0OD